What is CAI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 8.39B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CAI?

P/E (TTM) is 79.83 and 52-week range is $14.19 to $33.65 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CAI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CAI?

The company profile lists revenue (TTM) near $989M, net income (TTM) near $105M, EPS (TTM) near $0.37 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Caris Life Sciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Irving, Texas, US, 282.7M shares outstanding, ISIN US1421521071 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Caris Life Sciences Inc

$CAI

Health Care · Biotechnology

Run Scenarios

$29.70

+8.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. The company is headquartered in Irving, Texas and currently employs 1,846 full-time employees. The company went IPO on 2025-06-18. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Employees

1,846

Website

www.carislifesciences.com/

IPO

2025-06-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)